Bladder Cancer Market, By Type (Transitional Cell Carcinoma, Invasive Bladder Cancer, Superficial Bladder Cancer, Adenocarcinomax, and Other Rare Types), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Radical Cystectomy, and Others), By Diagnosis (Urine Lab Tests, Cystoscopy, Biopsy, Imaging Test, and Others), By End User (Hospital, Clinic, Cancer Care Centers, and Others) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America). The global Bladder Cancer market size was estimated at USD 5.25 billion in 2023 and is projected to reach USD 7.52 billion in 2030 at a CAGR of 4.60% during the forecast period 2023-2030.
Request Samples Pages of the Report: https://www.delvens.com/get-free-sample/bladder-cancer-market-trends-forecast-till-2030
Bladder cancer occurs when the cells that make up the bladder begin to multiply uncontrollably. More cancer cells can form a tumor and spread to other parts of the body over time. The bladder wall consists of several layers. Each layer consists of several types of cells. The urothelium, or transitional epithelium, lining the inside of the bladder is where most bladder malignancies begin. Cancer progresses to a higher stage, progresses, and is more difficult to treat when it spreads to or through other layers of the bladder wall. Over time, cancer can spread outside the bladder and into adjacent structures. It can spread to nearby lymph nodes or other organs.
The bladder cancer therapeutics and diagnostics market may witness rapid growth due to the increasing awareness about bladder diseases and available therapies, along with growing healthcare expenditure and the growing burden of bladder cancer. For instance, in March 2022, the 'Don't Go Red' theme for Bladder Cancer Awareness has been declared by World Bladder Cancer Patient Coalition to raise awareness of warning signs and symptoms, as early detection is critical for enhancing long-term survival and quality of life. Such initiatives are expected to boost market growth over the forecast period.
The spread of the COVID-19 pandemic had a significant impact on the bladder cancer market. During the first wave, the surgical volume was not compromised. Treatment-related alterations were kept to a minimum and adhered to the revised guidelines. During the peak of the COVID-19 pandemic in 2020, more than a quarter of patients with bladder cancer experienced care delays in the United States. As a result of the pandemic, the market for bladder cancer therapeutics and diagnostics had been significantly impacted.
Delvens Industry Expert's Standpoint
The pandemic had a considerable impact on businesses globally, with nations like India and China bearing the brunt of the virus's outbreak. Factors such as increasing incidence of bladder cancer, growing awareness about cancer and its available treatments, rising healthcare costs, increasing smoking and tobacco consumption are expected to accelerate the maturation of the global bladder cancer market. Additionally, the prevalence of bladder cancer across the world supports the expansion of the market during the forest season. For example, the Global Cancer Observatory Statistics 2020 reports that bladder cancer and prostate cancer are among the 10 most common cancers in the world. The same source also reports that the number of new cases of bladder cancer was estimated to be 573,278 in 2020 and the number of prostate cancer cases was 1,414,259 in both sexes in 2020. Such a high incidence of cancer worldwide will drive the market over time. Additionally, increasing focus of key players on various growth strategies such as R&D and product approval is expected to further boost the market. These factors have led to the expansion of the market and increased demand for Bladder Cancer solutions.
Bladder Cancer Market Key Findings
- The type segment is further fragmented into Transitional Cell Carcinoma, Invasive Bladder Cancer, Superficial Bladder Cancer, Adenocarcinomax, and Other Rare Types. The Transitional Cell Carcinoma, Invasive Bladder Cancer, Superficial Bladder Cancer, Adenocarcinomax, and Other Rare Types segment is expected to account for a larger market size during the forecast period. Healthcare infrastructures in wealthy and developing countries have improved as a result. The superficial bladder cancer segment will witness rapid growth in the global bladder cancer drugs market during the forecast period. The expansion of this segment is due to the growing awareness of superficial bladder diseases, improvement of healthcare infrastructures in developed and developing countries, and technological advancements.
- The Treatment segment is further bifurcated into Chemotherapy, Radiation Therapy, Immunotherapy, Radical Cystectomy, and Others. The Chemotherapy is the largest market during the forecast period. Several chemotherapy drugs of 2021 are to blame for this. On the other hand, the bladder cancer treatment market is expected to show a good growth rate in the immunotherapy category. Increasing incidence of target diseases, growing preference for immunotherapy over traditional treatments, and growing demand for monoclonal antibodies and biosimilars are the major drivers for the growth of the immunotherapy segment.
- The diagnosis segment is further bifurcated into Urine Lab Tests, Cystoscopy, Biopsy, Imaging Test, and Others. Cystoscopy to account for a larger market size during the forecast period. During the procedure known as cystoscopy, a telescope is used to look inside the bladder and urethra. For a direct visual examination of the urothelium, a cystoscope is a special endoscope that is inserted into the bladder through the urethra. Cystoscopy is economical. Increasing use of cystoscopy, increasing incidence of bladder cancer and product debuts by major market players are contributing to the growth of this market segment.
- The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. Due to the region's expanding R&D activities and well-established healthcare infrastructure.
To Understand the Business Strategies, Make an Inquiry for the Report: https://www.delvens.com/Inquire-before-buying/bladder-cancer-market-trends-forecast-till-2030
Bladder Cancer Market Regional Analysis
North America to Dominate the Market
- North America is estimated to account for the largest market share during the forecast period. Due to the region's expanding R&D activities and well-established healthcare infrastructure.
- Moreover, the existence of numerous biologics and biopharmaceutical firms is another factor that has contributed to the bladder cancer therapies and diagnostics market's size and stellar growth.
Bladder Cancer Market Competitive Landscape
- Abbott Inc.
- Accord Healthcare
- Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bedford Lab
- Bristol-Myers Squibb Company
- Celgene Corporation
- Eli Lilly and Company
- Endo Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline PLC
- Hoffmann-La Roche AG
- Johnson & Johnson (Janssen Pharmaceutical)
- Merck & Co. Inc
- Novartis International AG
- Pfizer Inc.
- Sanofi S.A.
Recent Developments
- In July 2022, The United States Food and Drug Administration (FDA) agreed to review ImmunityBio's Biologics License Application (BLA) for N-803 in patients with or without Ta or T1 illness who have non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS).
- In July 2022, Nanostics Inc., launched a prospective clinical study designed to validate a novel and minimally invasive bladder cancer diagnostic test, ClarityDX Bladder, using its ClarityDX diagnostic platform. In partnership with the University of Alberta’s Alberta Prostate Cancer Research Initiative (APCaRI) and DynaLIFE Medical Labs.
Purchase the Research Report at: https://www.delvens.com/checkout/bladder-cancer-market-trends-forecast-till-2030
Reasons to Acquire
- Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
- Gain authentic and granular data access for the Bladder Cancer Market to understand the trends and the factors involved in changing market situations.
- Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
- In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.
Bladder Cancer Market Report Scope
The Bladder Cancer Market is segmented into various segments such as type, Treatment, diagnosis, end user, and region:
Based on Type
- Transitional Cell Carcinoma
- Invasive Bladder Cancer
- Superficial Bladder Cancer
- Adenocarcinomax
- Other Rare Types
Based on the Treatment
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Radical Cystectomy
- Others
Based on the Diagnosis
- Urine Lab Tests
- Cystoscopy
- Biopsy
- Imaging Test
- Others
Based on End User
- Hospital
- Clinic
- Cancer Care Centers
- Others
Read Trending Reports:
https://www.delvens.com/report/laboratory-freezers-market-trends-forecast-till-2028
https://www.delvens.com/report/peripheral-vascular-devices-market-trends-forecast-till-2028
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact Us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
Research Nester released a report titled “Metastatic Bladder Cancer Market: Global Demand Analysis & Opportunity Outlook 2029” which delivers detailed overview of the global metastatic bladder cancer market in terms of market segmentation by cancer type, treatment type, and region.Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.The metastatic bladder cancer market is projected to grow with a moderate CAGR during the forecast period, i.e., 2021-2029, on account of the rising elderly population and the increasing investment in the developing of new therapies.
The high incidence of urothelial carcinoma can be linked to the increasing tobacco consumption globally which is a major risk factor for it.
On the basis of treatment type, the market is segmented into surgery, chemotherapy, immunotherapy, radiotherapy, targeted therapy, and others.Download Sample of This Strategic Report: https://www.researchnester.com/sample-request-3022On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, out of which, the metastatic bladder cancer market in the Asia Pacific is projected to grow at the highest CAGR throughout the forecast period.
This can be attributed to the presence of leading healthcare providers in the region, especially in the United States, who are extensively involved in the research and development for innovative metastatic bladder cancer treatment procedures.Rising Elderly Population and Increasing Investment in the Development of New Therapies to Drive Market GrowthAccording to the United Nations, it is estimated that by 2050, every one in six people will be 65 years or older, i.e., 16% of the total world population.
Along with this, the number of persons above 80 years or older is also projected to triple by the end of 2050.Age is one of the most predominant risk factors for the development of metastatic bladder cancer.
Additionally, the increasing investment in research and development relating to metastatic bladder cancer in recent years is also expected to boost the market growth in upcoming years.
